Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Protean Select. This analysis is provided for institutional research purposes only and is not investment advice.
"Protean navigated a soft September by adding to beaten-down MedTech positions on conviction and covering highly profitable investment company shorts, remaining focused on nimble portfolio adjustments."
In their September 2025 letter, Protean Funds reports minor monthly drawdowns (-1.4% for Protean Small Cap and -1.2% for Protean Select) but maintains solid year-to-date outperformance. The manager reflects on the discipline required for 'grinding out' returns in range-bound markets. They detail their investment of approximately 18% of the portfolio in Nordic MedTech names, asserting that while being 'early and wrong' is painful in the short-term, these quality franchises are near a valuation floor. Significant updates include covering their profitable shorts in Swedish investment companies, initiating positions in Chemometec and Electrolux Professional, and detailing a major thesis on Getinge's potential to double over the next two years as quality-related costs normalize.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Protean navigated a soft September by adding to beaten-down MedTech positions on conviction and covering highly profitable investment company shorts, remaining focused on nimble po...
Growth Outlook
Market outlook remains moderate conviction: Protean navigated a soft September by adding to beaten-down MedTech positions on conviction and covering highly profitable investment company shorts, remaining focused on nimble po...
Risk Appetite
Risk appetite posture is above average conviction: Protean navigated a soft September by adding to beaten-down MedTech positions on conviction and covering highly profitable investment company shorts, remaining focused on nimble po...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Protean navigated a soft September by adding to beaten-down MedTech positions on conviction and covering highly profitable investment company shorts, remaining focused on nimble po...
Forward Guidance
Forward guidance signal: Protean navigated a soft September by adding to beaten-down MedTech positions on conviction and covering highly profitable investment company shorts, remaining focused on nimble po...
Language Signal
Tone analysis indicates above average conviction language: Protean navigated a soft September by adding to beaten-down MedTech positions on conviction and covering highly profitable investment company shorts, remaining focused on nimble po...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Protean navigated a soft September by adding to beaten-down MedTech positions on conviction and covering highly profitable investment company shorts, remaining focused on nimble po...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. Protean navigated a soft September by adding to beaten-down MedTech positions on conviction and covering highly profitable investment company shorts, remaining focused on nimble po...
Time Horizon
Investment time horizon reflects a above average conviction orientation. Protean navigated a soft September by adding to beaten-down MedTech positions on conviction and covering highly profitable investment company shorts, remaining focused on nimble po...
